- Home
- CRIS vs NYC Comparison
CRIS vs NYC Comparison
Compare CRIS & NYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- NYC
- Stock Information
- Founded
- CRIS 2000
- NYC 2013
- Country
- CRIS United States
- NYC United States
- Employees
- CRIS N/A
- NYC N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- NYC Real Estate
- Sector
- CRIS Health Care
- NYC Finance
- Exchange
- CRIS Nasdaq
- NYC Nasdaq
- Market Cap
- CRIS 22.9M
- NYC 25.5M
- IPO Year
- CRIS 2000
- NYC N/A
- Fundamental
- Price
- CRIS $1.67
- NYC $9.64
- Analyst Decision
- CRIS Strong Buy
- NYC
- Analyst Count
- CRIS 2
- NYC 0
- Target Price
- CRIS $16.50
- NYC N/A
- AVG Volume (30 Days)
- CRIS 76.7K
- NYC 4.5K
- Earning Date
- CRIS 11-13-2025
- NYC 11-11-2025
- Dividend Yield
- CRIS N/A
- NYC N/A
- EPS Growth
- CRIS N/A
- NYC N/A
- EPS
- CRIS N/A
- NYC N/A
- Revenue
- CRIS $11,405,000.00
- NYC $54,865,000.00
- Revenue This Year
- CRIS $1.41
- NYC $8.40
- Revenue Next Year
- CRIS $7.46
- NYC $1.62
- P/E Ratio
- CRIS N/A
- NYC N/A
- Revenue Growth
- CRIS 12.24
- NYC N/A
- 52 Week Low
- CRIS $1.02
- NYC $7.89
- 52 Week High
- CRIS $6.44
- NYC $16.30
- Technical
- Relative Strength Index (RSI)
- CRIS 45.61
- NYC 36.79
- Support Level
- CRIS $1.63
- NYC $9.11
- Resistance Level
- CRIS $1.95
- NYC $10.50
- Average True Range (ATR)
- CRIS 0.15
- NYC 0.84
- MACD
- CRIS 0.00
- NYC -0.03
- Stochastic Oscillator
- CRIS 17.65
- NYC 24.71
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.